Novo Nordisk, Eli Lilly slide after Trump comments on weight loss drug pricing
Monia Brett P, Chief Executive Officer of Ionis Pharmaceuticals Inc (NASDAQ:IONS), sold 206,914 shares of common stock on September 3, 2025, for a total of $12,294,703. The sales occurred at weighted average prices ranging from $59.119 to $61.0629 per share, with the stock trading near its 52-week high of $62.08. According to InvestingPro data, IONS has shown remarkable momentum with a 39.2% return in the past week.
The CEO also exercised options to acquire a total of 203,814 shares of Ionis Pharmaceuticals common stock at prices ranging from $32.6 to $53.77, for a total value of $9,032,038.
These transactions are detailed in a Form 4 filing with the Securities and Exchange Commission.
In other recent news, Ionis Pharmaceuticals has reported significant developments regarding its drug trials and analyst ratings. The company announced positive topline results from its Phase 3 CORE and CORE2 trials for severe hypertriglyceridemia, which demonstrated significant triglyceride lowering and reduced acute pancreatitis risk. Following these promising results, RBC Capital raised its price target for Ionis Pharmaceuticals to $80, citing the drug’s potential in treating acute pancreatitis. H.C. Wainwright also increased its price target to $95, acknowledging the strong triglyceride reductions observed in the pivotal studies.
Additionally, BMO Capital upgraded Ionis Pharmaceuticals from Market Perform to Outperform, highlighting the blockbuster potential of Olezarsen. Oppenheimer also adjusted its price target to $81, maintaining an Outperform rating after the positive Phase 3 trial results for Tryngolza. These developments reflect growing confidence among analysts in Ionis Pharmaceuticals’ drug pipeline and its potential impact on the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.